ExCellThera's Zemcelpro Receives Conditional Marketing Authorization in Europe for Allogeneic Umbilical Cord Blood-Derived Cell Therapy
ExCellThera's Innovative Stem Cell Therapy Approved in Europe
The European Medicines Agency (EMA) has granted conditional marketing authorization for 'Zemcelpro' (active ingredient: dorocubicel), developed by Cordex Biologics, a subsidiary of Canadian biotechnology company ExCellThera. This approval represents a significant milestone, offering a new treatment option for adult patients with high-risk hematological malignancies who are ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT) due to a lack of suitable donors. Zemcelpro is an advanced therapy medicinal product (ATMP) developed to overcome the limitations of single umbilical cord blood units, which often have a low cell count, and to improve engraftment rates.
The Value of Molecular Technology in Hematopoietic Stem Cell Expansion
Zemcelpro utilizes a proprietary small molecule compound, 'UM171,' to ex vivo expand hematopoietic stem cells (CD34+ stem cells) and is manufactured as a cryopreserved, personalized cell therapy mixed with unexpanded cells. This technology minimizes the risk of genetic mutations during the culture process while providing a sufficient number of stem cells for transplantation, thereby inducing rapid engraftment of neutrophils and platelets. This is considered a significant technological advancement, offering a treatment opportunity to hematological malignancy patients who previously had to forgo umbilical cord blood transplantation due to insufficient cell counts.
Efficacy and Safety Demonstrated Through Phase 2 Clinical Data
This conditional approval is based on positive topline results from a Phase 2 clinical trial involving 60 patients with high-risk hematological malignancies. The clinical results showed an overall survival (OS) rate of 63.7% and a progression-free survival (PFS) rate of 57.0% at 24 months post-transplantation. Notably, in patients under 43 years of age, the non-relapse mortality rate was 0%, and the 24-month OS rate was 82.8%. Although this is a conditional approval, requiring the submission of additional data from a randomized controlled trial and a patient registry, it is noteworthy that Zemcelpro has demonstrated clear clinical benefit compared to standard treatment.
Commercial Partnerships and Prospects for the Global Allogeneic Stem Cell Market
ExCellThera has already taken steps to expand its market presence, including signing an exclusive commercialization license agreement with Medexus Pharmaceuticals (MDP), a Canadian pharmaceutical company, in June 2026. With the global allogeneic hematopoietic stem cell transplantation market estimated at approximately $4.89 billion in 2026, Zemcelpro is expected to engage in intense competition with Gamida Cell's FDA-approved therapy, Omisirge (active ingredient: omidubicel). Zemcelpro's entry into the European market is expected to serve as a positive catalyst, establishing commercial production standards for allogeneic cell therapies and lowering the barriers to entry for related platform companies in Europe.
The conditional marketing authorization for Zemcelpro in Europe will mark the beginning of a competitive landscape in the global allogeneic hematopoietic stem cell transplantation market, valued at approximately $4.89 billion, with Gamida Cell's Omisirge. In the short term, Zemcelpro can maximize market penetration based on the 24-month overall survival rate of 63.7% and neutrophil engraftment rate data confirmed in the Phase 2 clinical trial, and expansion into the North American market is expected to accelerate through the license agreement with Medexus in Canada. In the medium to long term, securing confirmatory Phase 3 clinical data, a condition for approval, remains a challenge. However, with the approval of the innovative stem cell expansion technology based on the small molecule UM171, investment in research and development by related platform companies is expected to be further activated. The favorable attitude of regulatory agencies towards allogeneic cell therapies will promote the reduction of manufacturing costs and the widespread availability of off-the-shelf products, driving the growth of the precision medicine industry.
Source: EMA (ema)